Discovery of FX-111, a first-in-class heterobifunctional degrader of transcriptionally active androgen receptor (ARON), to treat patients with AR-driven prostate cancer
AsherBio
Phase 0 Intratumoral Microdevice Study of FX-909 in Bladder Cancer Demonstrates On-Target Anti-Tumor Activity and Immune Modulation, Enhanced in Combination with Anti-PD-1
AsherBio
AR copy number amplification and AR/KLK3 expression patterns reveal mechanisms of AR signaling inhibitor (ARSI) resistance and highlight the need for AR-directed therapeutic innovation in metastatic castration resistance prostate cancer (mCRPC)
AsherBio
Phase 1 Clinical Data Show FX-909, a First-in-Class Oral PPARG Inhibitor, Drives Immune Modulation and Pro-Inflammatory Cytokine Induction in IO-Experienced Patients with Advanced Urothelial Carcinoma
AsherBio
Safety and Clinical Activity of FX-909, a First-in-Class Oral Small Molecule Inhibitor of Peroxisome Proliferator-Activated Receptor Gamma (PPARG), the Master Regulator of Luminal Lineage, in Patients with Advanced Urothelial Carcinoma
AsherBio
Genomic peroxisome proliferator-activated receptor gamma (PPARG) study: A sponsored testing program to identify patients harboring genetic alterations in advanced UC in support of the FX-909 Phase 1 study
AsherBio
PPARG-High Circulating Monocytes Exhibit An Immunosuppressive Phenotype In Urothelial Cancer Patients Treated with Anti-PD1
AsherBio
A Phase 1, First-in-Human, Dose-Escalation and Expansion Study of FX-909 in Patients with Advanced Solid Malignancies, Including Advanced Urothelial Carcinoma
AsherBio
PPARG Amplification is Associated with Lack of Response to Anti-PD1 in Muscle-Invasive Urothelial Cancer
AsherBio
AI Analysis of Histological Images Accurately Identifies Luminal Subtype Urothelial Carcinomas Characterized by High PPARG Expression